elliotwaves study ERIS LIFESCIENCES
of the 5 waves corrective wave 3-4 and impulse 4-5 is pending. the final cycle in this stock can be expected to be complete by Jan2029 as it is cyclical in nature. We can confirm as long as wave 4 doesn't cross wave1.
The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market.
The company focuses on branded generics, with 85% in chronic and 15% in acute segments. It offers drugs across various therapies, including anti-diabetes, cardiovascular, dermatology, gastroenterology, gynecology, and anti-infective
The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market.
The company focuses on branded generics, with 85% in chronic and 15% in acute segments. It offers drugs across various therapies, including anti-diabetes, cardiovascular, dermatology, gastroenterology, gynecology, and anti-infective
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.